isoplexis eBook cover

Sponsor:

IsoPlexis Logo

In developing immunotherapies, processes and biomarkers are made more complex by the highly heterogenous T cells that form the basis for the therapeutic product, or that drive the anti-tumor response in various checkpoint and antibody based immunotherapies. IsoPlexis’ next generation systems provide actionable potency, safety, and patient difference metrics by detecting highly potent singlecell functional subsets for the first time. This is making a drastic difference in the pre-clinical to clinical pipeline, accelerating the development of novel immunotherapies.

Get the eBook

This site uses Akismet to reduce spam. Learn how your comment data is processed.